Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.23
- Piotroski Score 3.00
- Grade Buy
- Symbol (IONS)
- Company Ionis Pharmaceuticals, Inc.
- Price $38.01
- Changes Percentage (-1.11%)
- Change -$0.43
- Day Low $37.58
- Day High $38.12
- Year High $54.44
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $55.00
- High Stock Price Target $77.00
- Low Stock Price Target $28.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.67
- Trailing P/E Ratio -14.59
- Forward P/E Ratio -14.59
- P/E Growth -14.59
- Net Income $-366,286,000
Income Statement
Quarterly
Annual
Latest News of IONS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Better Artificial Intelligence (AI) Stock: Zoom Video Communications vs. Twilio
The rise of AI has driven tech stocks, with Nasdaq-100 Technology Sector index gaining 77%. However, not all tech stocks like Zoom and Twilio have seen significant growth post-pandemic....
By Yahoo! Finance | 3 hours ago -
TG Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
The profit margin for TG Therapeutics decreased to 4.6% from 69% in 3Q 2023 due to higher expenses. Revenue exceeded estimates by 2.7%, but EPS missed by 28%....
By Yahoo! Finance | 4 hours ago -
Five Bengals midseason predictions: Joe Burrow will battle Lamar Jackson for MVP
The Bengals are facing a crucial second half of the season at 4-5, aiming for a playoff spot. Joe Burrow's stellar performance and potential MVP contention, alongside defensive improvements, are key f...
By The New York Times | 4 hours ago
